BidaskClub upgraded shares of Celldex Therapeutics (NASDAQ:CLDX) from a hold rating to a buy rating in a report published on Saturday morning, BidAskClub reports.

Several other equities analysts have also recently issued reports on CLDX. HC Wainwright reissued a buy rating and set a $16.00 target price (down from $19.00) on shares of Celldex Therapeutics in a research note on Friday, March 27th. Zacks Investment Research cut Celldex Therapeutics from a hold rating to a sell rating in a research note on Thursday, June 18th. Cantor Fitzgerald boosted their target price on Celldex Therapeutics from $8.00 to $12.00 and gave the company an overweight rating in a research note on Friday, June 12th. Finally, ValuEngine cut Celldex Therapeutics from a buy rating to a hold rating in a research note on Saturday, June 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average target price of $10.33.

Shares of Celldex Therapeutics stock opened at $13.00 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.12 and a quick ratio of 5.12. The business’s 50 day simple moving average is $5.38 and its two-hundred day simple moving average is $3.03. The stock has a market capitalization of $293.28 million, a P/E ratio of -4.39 and a beta of 3.08. Celldex Therapeutics has a one year low of $1.50 and a one year high of $13.91.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.02). Celldex Therapeutics had a negative return on equity of 47.60% and a negative net margin of 948.81%. The company had revenue of $2.73 million during the quarter, compared to analysts’ expectations of $1.28 million. Sell-side analysts expect that Celldex Therapeutics will post -3.09 earnings per share for the current fiscal year.

In other news, CEO Anthony S. Marucci purchased 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were bought at an average cost of $2.99 per share, for a total transaction of $44,850.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Samuel Bates Martin purchased 9,750 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were purchased at an average price of $2.99 per share, for a total transaction of $29,152.50. The disclosure for this purchase can be found here. Insiders have purchased 41,170 shares of company stock worth $126,778 over the last 90 days. 2.40% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CLDX. Acadian Asset Management LLC boosted its holdings in Celldex Therapeutics by 20.4% in the first quarter. Acadian Asset Management LLC now owns 298,649 shares of the biopharmaceutical company’s stock worth $496,000 after acquiring an additional 50,583 shares in the last quarter. TSP Capital Management Group LLC boosted its holdings in Celldex Therapeutics by 14.9% in the first quarter. TSP Capital Management Group LLC now owns 410,017 shares of the biopharmaceutical company’s stock worth $681,000 after acquiring an additional 53,127 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Celldex Therapeutics by 8.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,115,368 shares of the biopharmaceutical company’s stock worth $2,487,000 after acquiring an additional 89,083 shares in the last quarter. Institutional investors own 20.99% of the company’s stock.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

See Also: How liquidity affects the bid-ask spread

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.